The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional)
This funding opportunity announcement (FOA) invites applications for the Technology Research Site component of the NIH Back Pain Consortium (BACPAC) Research Program. BACPAC is a patient centric-research program that will focus on translational and clinical research for discovery of chronic low back pain (cLBP) mechanisms, and on identification and testing of new interventions targeted to the individual patient. The Research Program will utilize novel analytics and technologies to extensively phenotype patients with low back pain, develop an integrated model of cLBP, produce new and improved diagnostic and treatment algorithms, and will conduct traditional Phase 2 Clinical Trials as well as sequential, adaptive, phase 2/proof of concept clinical studies in stratified patient populations.
The Technology Research Sites (Tech Sites) will develop, test and deploy novel analytic tools, technologies and/or methods (TTM) that will improve our understanding of mechanisms of cLBP. Collectively, they will contribute to the development of an integrated model of cLBP. The technology research and development will run in parallel and will synergize with projects supported in the BACPAC Mechanistic Research Centers, the Data Integration, Algorithm Development and Operations Management Center and the Phase 2 Clinical trials. Successful analytic TTM will be utilized clinically in BACPAC Phase 2 Clinical Trials and in multimodal, sequential, adaptive clinical studies in stratified patient populations. Where applicable, TTM developed by the Tech Sites will improve the diagnosis, treatment and prevention of recurrences of cLBP and/or be useful for defining different mechanisms in different patients and contribute to the development of algorithms for individualized treatment plans.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): March 20, 2019
RFA-AR-19-028 Expiration Date March 21, 2019